Outcomes of intravenous recombinant tissue plasminogen activator therapy according to gender: A clinical registry study and systematic Review

Stroke

Volumn 40, Issue 6, 2009, Pages 2104-2110

  Meseguer, Elena ^a,b   Mazighi, Mikael ^a,b   Labreuche, Julien ^a,b   Arnaiz, Carlos ^a,b   Cabrejo, Lucie ^a,b   Slaoui, Tarik ^a,b   Guidoux, Celine ^a,b   Olivot, Jean Marc ^a,b   Abboud, Halim ^a,b   Lapergue, Bertrand ^a,b   Raphaeli, Guy ^a,b   Klein, Isabelle F ^a,b   Lavallée, Philippa C ^a,b   Amarenco, Pierre ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

acute cerebral infarction; Thrombolysis

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REGISTER; SEX DIFFERENCE; SYSTEMATIC REVIEW; COMPUTER ASSISTED TOMOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PROSPECTIVE STUDY; REVIEW; STATISTICAL ANALYSIS; STROKE; TREATMENT OUTCOME;

AGED; DATA INTERPRETATION, STATISTICAL; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; REGISTRIES; SEX FACTORS; STROKE; TISSUE PLASMINOGEN ACTIVATOR; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 66849109418     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.546325     Document Type: Article

References (39)

1. Kent DM, Price LL, Ringleb P, Hill MD, Selker HP. Sex-based differences in response to recombinant tissue plasminogen activator in acute ischemic stroke: a pooled analysis of randomized clinical trials. Stroke 2005;36:62-65.
2. Niewada M, Kobayashi A, Sandercock PA, Kaminski B, Czlonkowska A. Influence of gender on baseline features and clinical outcomes among 17 370 patients with confirmed ischaemic stroke in the international stroke trial. Neuroepidemiology. 2005;24:123-128.
3. Kapral MK, Fang J, Hill MD, Silver F, Richards J, Jaigobin C, Cheung AM. Sex differences in stroke care and outcomes: results from the registry of the Canadian Stroke Network. Stroke 2005;36:809-814.
4. Elkind MS, Prabhakaran S, Pittman J, Koroshetz W, Jacoby M, Johnston KC. Sex as a predictor of outcomes in patients treated with thrombolysis for acute stroke. Neurology. 2007;68:842-848.
5. Kent DM, Buchan AM, Hill MD. The gender effect in stroke thrombolysis: of cases, controls, and treatment-effect modification. Neurology. 2008;71:1080-1083.
6. Di Legge S, Saposnik G, Nilanont Y, Hachinski V. Neglecting the difference: does right or left matter in stroke outcome after thrombolysis? Stroke 2006;37:2066-2069.
7. Savitz SI, Schlaug G, Caplan L, Selim M. Arterial occlusive lesions recanalize more frequently in women than in men after intravenous tissue
8. plasminogen activator administration for acute stroke. Stroke 2005;36: 1447-1451.
9. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study group. NEnglJMed. 1995;333:1581-1587.
10. Ernon L, Schrooten M, Thijs V. Body temperature and outcome after stroke thrombolysis. Acta Neurol Scand. 2006;114:23-28.
11. Engelter ST, Reichhart M, Sekoranja L, Georgiadis D, Baumann A, Weder B, Muller F, Luthy R, Arnold M, Michel P, Mattle HP, Tettenborn B, Hungerbuhler HJ, Baumgartner RW, Sztajzel R, Bogousslavsky J, Lyrer PA. Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis. Neurology. 2005;65:1795-1798.
12. Berrouschot J, Rother J, Glahn J, Kucinski T, Fiehler J, Thomalla G. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or =80 years) stroke patients. Stroke 2005;36:2421-2425.
13. Lansberg MG, Albers GW, Wijman CA. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis. 2007;24:1-10.
14. Gomez-Choco M, Obach V, Urra X, Amaro S, Cervera A, Vargas M, Chamorro A. The response to IV rt-PA in very old stroke patients. Eur J Neurol. 2008;15:253-256.
15. Uyttenboogaart M, Koch MW, Koopman K, Vroomen PC, De Keyser J, Luijckx GJ. Safety of antiplatelet therapy prior to intravenous thrombolysis in acute ischemic stroke. Arch Neurol. 2008;65:607-611.
16. Caso V, Paciaroni M, Venti M, Palmerini F, Silvestrelli G, Milia P, Biagini S, Agnelli G. Determinants of outcome in patients eligible for thrombolysis for ischemic stroke. Vasc Health Risk Manag. 2007;3: 749 -754.
17. Marti-Fabregas J, Bravo Y, Cocho D, Marti-Vilalta JL, Diaz-Manera J, San Roman L, Puig M, Blanco M, Castellanos M, Millan M, Roquer J, Obach V, Maestre J. Frequency and predictors of symptomatic intrace- rebral hemorrhage in patients with ischemic stroke treated with recom- binant tissue plasminogen activator outside clinical trials. Cerebrovasc Dis. 2007;23:85-90.
18. Georgiadis D, Engelter S, Tettenborn B, Hungerbuhler H, Luethy R, Muller F, Arnold M, Giambarba C, Baumann CR, von Budingen HC, Lyrer P, Baumgartner RW. Early recurrent ischemic stroke in stroke patients undergoing intravenous thrombolysis. Circulation. 2006;114: 237-241.
19. Saposnik G, Di Legge S, Webster F, Hachinski V. Predictors of major neurologic improvement after thrombolysis in acute stroke. Neurology. 2005;65:1169 -1174.
20. Heuschmann PU, Kolominsky-Rabas PL, Roether J, Misselwitz B, Low- itzsch K, Heidrich J, Hermanek P, Leffmann C, Sitzer M, Biegler M, Buecker-Nott HJ, Berger K. Predictors of in-hospital mortality in patients with acute ischemic stroke treated with thrombolytic therapy. JAMA. 2004;292:1831-1838.
21. Saposnik G, Young B, Silver B, Di Legge S, Webster F, Beletsky V, Jain V, Nilanont Y, Hachinski V. Lack of improvement in patients with acute stroke after treatment with thrombolytic therapy: predictors and association with outcome. JAMA. 2004;292:1839 -1844.
22. Tanne D, Kasner SE, Demchuk AM, Koren-Morag N, Hanson S, Grond M, Levine SR. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the multicenter rt-PA stroke survey. Circulation. 2002;105:1679-1685.
23. Demchuk AM, Tanne D, Hill MD, Kasner SE, Hanson S, Grond M, Levine SR. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology. 2001;57:474-480.
24. Mendizabal JE, Lurie DN, Greiner FG, Shah AK, Zweifler RM. Baseline computed tomography changes and clinical outcome after thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke. J Neuroimaging. 2001;11:101-104.
25. Chiu D, Krieger D, Villar-Cordova C, Kasner SE, Morgenstern LB, Bratina PL, Yatsu FM, Grotta JC. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998;29:18 -22.
26. Wahlgren N, Ahmed N, Eriksson N, Aichner F, Bluhmki E, Davalos A, Erila T, Ford GA, Grond M, Hacke W, Hennerici MG, Kaste M, Kohrmann M, Larrue V, Lees KR, Machnig T, Roine RO, Toni D, Vanhooren G. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials. Safe Implementation of Thrombolysis in Stroke-Monitoring Study (sits-most). Stroke 2008;39:3316-3322.
27. Trouillas P, Nighoghossian N, Derex L, Adeleine P, Honnorat J, Neus- chwander P, Riche G, Getenet JC, Li W, Froment JC, Turjman F, Malicier D, Fournier G, Gabry AL, Ledoux X, Berthezene Y, Ffrench P, Dechavanne M. Thrombolysis with intravenous rtPA in a series of 100 cases of acute carotid territory stroke: determination of etiological, topographic, and radiological outcome factors. Stroke 1998;29:2529-2540.
28. Schellinger PD, Chalela JA, Kang DW, Latour LL, Warach S. Diagnostic and prognostic value of early MR imaging vessel signs in hyperacute stroke patients imaged <3 hours and treated with recombinant tissue plasminogen activator. AJNR Am J Neuroradiol. 2005;26:618-624.
29. Saqqur M, Uchino K, Demchuk AM, Molina CA, Garami Z, Calleja S, Akhtar N, Orouk FO, Salam A, Shuaib A, Alexandrov AV. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke 2007;38:948-954.
30. Saqqur M, Molina CA, Salam A, Siddiqui M, Ribo M, Uchino K, Calleja S, Garami Z, Khan K, Akhtar N, O'Rourke F, Shuaib A, Demchuk AM, Alexandrov AV. Clinical deterioration after intravenous recombinant tissue plasminogen activator treatment: a multicenter transcranial Doppler study. Stroke 2007;38:69-74.
31. Millan M, Sobrino T, Castellanos M, Nombela F, Arenillas JF, Riva E, Cristobo I, Garcia MM, Vivancos J, Serena J, Moro MA, Castillo J, Davalos A. Increased body iron stores are associated with poor outcome after thrombolytic treatment in acute stroke. Stroke 2007;38:90-95.
32. Sobesky J, Frackowiak M, Zaro Weber O, Hahn M, Moller-Hartmann W, Rudolf J, Neveling M, Grond M, Schmulling S, Jacobs A, Heiss WD. The Cologne stroke experience: safety and outcome in 450 patients treated with intravenous thrombolysis. Cerebrovasc Dis. 2007;24:56-65.
33. Mouradian MS, Senthilselvan A, Jickling G, McCombe JA, Emery DJ, Dean N, Shuaib A. Intravenous rt-PA for acute stroke: comparing its effectiveness in younger and older patients. J Neurol Neurosurg Psychiatry. 2005;76:1234-1237.
34. Cocho D, Borrell M, Marti-Fabregas J, Montaner J, Castellanos M, Bravo Y, Molina-Porcel L, Belvis R, Diaz-Manera JA, Martinez-Domeno A, Martinez-Lage M, Millan M, Fontcuberta J, Marti-Vilalta JL. Pre- treatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator. Stroke 2006;37: 996-999.
35. Glader EL, Stegmayr B, Norrving B, Terent A, Hulter-Asberg K, Wester PO, Asplund K. Sex differences in management and outcome after stroke: a Swedish national perspective. Stroke 2003;34:1970-1975.
36. Hill MD, Kent DM, Hinchey J, Rowley H, Buchan AM, Wechsler LR, Higashida RT, Fischbein NJ, Dillon WP, Gent M, Firszt CM, Schulz GA, Furlan AJ; PROACT-2 Investigators. Sex-based differences in the effect of intra-arterial treatment of stroke: analysis of the PROACT-2 study. Stroke 2006;37:2322-2325.
37. Kain K, Carter AM, Bamford JM, Grant PJ, Catto AJ. Gender differences in coagulation and fibrinolysis in white subjects with acute ischemic stroke. J Thromb Haemost. 2003;1:390-392.
38. Kain K, Catto AJ, Carter AM, Young J, Bamford J, Bavington J, Grant PJ. Decreased fibrinolytic potential in south Asian women with ischaemic cerebrovascular disease. Br J Haematol. 2001;114:155-161.
39. Sawada M, Alkayed NJ, Goto S, Crain BJ, Traystman RJ, Shaivitz A, Nelson RJ, Hurn PD. Estrogen receptor antagonist ICI182780 exacerbates ischemic injury in female mouse. J Cereb Blood Flow Metab. 2000;20: 112-118.